Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supernus Adds To CNS Portfolio, Especially In Parkinson’s, With Adamas Buyout

Executive Summary

Building upon the May 2020 acquisition of US WorldMeds, Supernus is diversifying beyond Trokendi for epilepsy and will be able to rely on its existing commercial force for CNS products.

You may also be interested in...



Deal Watch: Menarini Enters US Oncology Market Via Merger With Stemline

Menarini/Stemline, Supernus/US WorldMeds, BioMarin/DiNOAQOR, Adicet/ResTORbio, Vertex/Affinia, Hansoh/NiKang, plus COVID-19 deals in brief and more.

Quite A Range: Adamas Ponders $10,000-$30,000 Price Tag For Gocovri

The US FDA approved the extended-release amantadine for levodopa-induced dyskinesia in Parkinson's disease. Adamas will finalize its pricing and begin selling the product later this year.

Supernus flies high on FDA OK for Trokendi XR in epilepsy

Investors rallied around shares of Supernus Pharmaceuticals in a big way on 19 August, with the company's stock soaring as high as 26.5% after the US FDA granted its approval for the Rockville, Maryland specialty pharma to market its once-daily extended release formulation of topiramate under the brand-name Trokendi XR as a treatment for patients with epilepsy.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145213

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel